<DOC>
	<DOCNO>NCT00353964</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness three concentration rEV131 , new investigational anti-inflammatory agent , compare placebo ( inactive substance ) FDA approve anti-inflammatory agent patient ocular inflammation undergone cataract extraction intra-ocular lens implantation .</brief_summary>
	<brief_title>Safety Efficacy Study rEV131 Treatment Ocular Inflammation After Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Capsule Opacification</mesh_term>
	<criteria>male female undergone unilateral cataract extraction phacoemulsification ( PHACO ) method implantation posterior chamber intraocular lens unstable glaucoma active bacterial and/or viral infection use ocular systemic antiinflammatory agent within 1 week prior enrollment duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>